Ablation Devices: Technologies and Global Markets https://www.reportbuyer.com/product/2009158/Ablation-Devices-Technologies-and-Global-Markets.html
Advertisement
STUDY AND OBJECTIVE: • Define and identify key market segments and market structure in ablation technologies.• Measure and estimate the global ablation market and its market segments, which include technologies, product categories, therapeutic markets and geographical segmentation.• Identify key market dynamics and the factors impacting the global ablation market and its subsegments.• To identify the trends, gaps and opportunities in each of the micromarkets.• To focus exclusively on geographical segmentation. Analyze trends and opportunities in major regions: North America, Europe, Asia and the Rest of the World (ROW).• To identify major stakeholders, product portfolio and recent developments, and draw a competitive landscape for the market leaders.
Advertisement
STUDY BACKGROUND: Ablation is a minimally invasive surgical technique that involves destruction or removal of dysfunctional tissues to treat life-threatening diseases such as cancers, atrial fibrillation, etc. It is also equally adopted for simple treatments in cosmetology, orthopedics, uterine fibroids, etc. There is an increase in prevalence and incident rates of lifestyle-oriented diseases and an increasing need to innovate minimally and noninvasive technologies to treat them. From 15% to 20% of ischemic strokes occur due to atrial fibrillation and about 12 million people in the U.S. are expected to suffer from this condition by 2050. Deaths due to cancers are reaching alarming rates across the globe. By the end of 2013, America is expected to have about 580,350 deaths due to cancer. With numerous technologies available to control and treat cardiovascular disorders and cancer, they still remain primary causes of death. Where conventional radiation therapies have been effective and been adopted due to high awareness levels, emerging technologies such as hydro-mechanical ablation, microwave and hydrothermal are increasing hopes among patients and healthcare service providers.An increasingly aging population on one side and increasing healthcare expenditure on the other is becoming a major burden to governments across various countries. The regulatory and financial environment is getting significantly complex even in developed economies with governments focusing on cost-containment measures. The ablation procedure in this scenario is expected to be significantly preferred due to cost effectiveness (compared to conventional surgical techniques), shorter hospital stays, shorter recovery time and lesser risk of blood loss and infections.A high level of economic instability, growing pockets of investment in developing economies and commercialization of next-generation technologies are compelling market participants to collaborate and leverage. The current scenario requires the market players to plan exclusive strategies after an in-depth understanding of geographical, regulatory, technology and other key market factors.
SCOPE OF THE REPORT: This research report presents an in-depth analysis of the global ablation market by technologies, product categories, therapeutic segments, key procedures and geographical markets. The report includes key technologies involved in thermal ablation techniques and nonthermal ablation techniques. The report discusses the role of supply chain members from manufacturers to surgeons. The report has an in-depth analysis of key companies operating in the global ablation market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and geographies such as the U.S., Europe and Japan.The ablation devices market is mainly segmented into two classes: thermal and nonthermal technologies. Thermal technologies are further segmented into electrical, radiation, radio frequency, light, ultrasound, microwave and hydrothermal. The nonthermal technology market is segmented into cryotherapy and hydromechanical. The ablation devices technology market is further segmented on the basis of products offered for in-depth analysis of technology markets during the analysis period. The market study is detailed for technology based on procedures as well as its further implication on the therapeutic area. These two segmentations are also discussed in detailed for the given period. The market is segmented by geographical region into the Americas, Europe, Asia-Pacific and ROW. Companies profiled in this report include ConMed Corp., Varian Medical Systems Inc., Medtronic Inc., BSD Medical Corp., Olympus Corp., Urologix Inc., C.R. Bard Inc. and others.
INTENDED AUDIENCE: The INTENDED AUDIENCE includes:• Ablation technologies and device manufacturers and potential entrants.• Dealers, distributors and service providers of ablation devices.• Robotics, life science and surgical companies.• Healthcare-oriented software and analytics companies.• Research institutes, associations and academicians.
SOURCE OF INFORMATION AND METHODOLOGY: The global ablation market was assessed and calculated through a bottom-up approach that involved identifying the market revenues of the micromarkets that make up the macromarkets. The following process was followed to ensure quality and consistency of estimates.• In-depth primary and secondary research was conducted.• Primary research included gathering intelligence from key market players. The participants of the interview include CEOs, key opinion leaders, product heads and directors.• Secondary research not only included collation of data from freely available sources but also paid subscription from specialized industry magazines and websites.• To best assure triangulation of market estimates, the derived values where again validated through primary research.• Key factors considered during market estimations were price, volumes, incidence and prevalence rates, number of procedures, etc.The geographical segmentation was assessed through various parameters such as the number of players in a particular region, incidence and prevalence rates, the extent of research activity occurring in that geography and future potential.
ANALYST CREDENTIALS: Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, and life sciences and chemical markets. She has frequently delivered research services that contain strategic recommendations and business strategies to assist the market players in forming beneficial strategies. Yojana holds a B.Sc degree in Biotechnology and a MBA degree in Marketing.
REPORT HIGHLIGHTS: The global market for ablation devices reached nearly 8.1 billion in 2012. This market is expected to grow to $8.8 billion in 2013 and $15.1 billion in 2018 with a compound annual growth rate (CAGR) of 11.3% for the five-year period, 2013 to 2018.This report provides:• An overview of the global market for ablation devices• Analyses of global market trends, with data from 2012, estiamtes for 2013, and projections of compound annual growth rates (CAGRs) through 2018• A breakdown of the market into segments such as types of technology, products, major market players, application, geography, and factors influencing demand• A look at factors inhibiting market growth such as pricing, reimbursement policies, and stringent regulatory impositions• Comprehensive company profiles of major players
TABLE OF CONTENTSCHAPTER 1 INTRODUCTION 2 STUDY AND OBJECTIVE 2STUDY BACKGROUND 2SCOPE OF THE REPORT 3INTENDED AUDIENCE 3SOURCE OF INFORMATION AND METHODOLOGY 3ANALYST CREDENTIALS 4RELATED BCC RESEARCH REPORTS 4BCC RESEARCH ONLINE SERVICES 4DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7 SUMMARY TABLE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 8SUMMARY FIGURE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICALREGION, 2012-2018 ($ MILLIONS) 8
CHAPTER 3 ABLATION MARKET OVERVIEW 11 ABLATION DEVICES: TECHNOLOGY TRENDS AND INNOVATIONS 11TYPES OF CONVENTIONAL SURGICAL PROCEDURES AND DRAWBACKS 13HEART SURGERY 13PLASTIC SURGERY 14BRAIN SURGERY 14CANCER SURGERY 15ORTHOPEDIC SURGERY 15GOVERNMENT REGULATIONS, MEDICAL ASSOCIATIONS, FOOD AND DRUGADMINISTRATION, AND INTERNATIONAL REGULATORY AGENCIES 16TABLE 1 DEVICES THAT ARE NOT YET APPROVED FOR THE TREATMENT OF ATRIALFIBRILLATION 17INDUSTRY STRUCTURE AND SUPPLY CHAIN PROCESS 18ROLE OF MANUFACTURERS 18ROLE OF DISTRIBUTORS 19ROLE OF RESEARCH INSTITUTES AND CONSULTANTS 19ROLE OF GOVERNMENTS 20ROLE OF HOSPITALS AND SURGEONS 20DEMOGRAPHICS, INCIDENCE AND PREVALENCE RATES AND OTHERPARAMETERS INFLUENCING MARKET GROWTH 21INCIDENCES AND PREVALENCE RELATING TO CANCERS 21TABLE 2 CANCER DEMOGRAPHICS IN THE U.S., 2013 (ESTIMATED) 21FIGURE 1 DEATHS DUE TO PROSTATE CANCER IN THE U.K., 2011 (%) 22INCIDENCES AND PREVALENCE RELATING TO CARDIOVASCULAR DISEASES 23TABLE 3 CARDIOVASCULAR DEMOGRAPHICS IN THE U.S. BY AGE, 2010 (%) 23TABLE 4 EUROPEAN UNION STATISTICS OF CARDIOVASCULAR DISEASES ANDCIRCULATORY DISEASES, 2010 24FIGURE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN ADULTS IN THE U.S.AGE GROUP 45-64 YEARS, 2000 AND 2010 (%) 24INCIDENCES AND PREVALENCE RELATING TO OPHTHALMOLOGY 25TABLE 5 VISUAL IMPAIRMENT STATISTICS U.S., 2000 AND 2010 25FIGURE 3 CAUSES OF VISUAL IMPAIRMENT, 2010 (%) 25FIGURE 4 VISUAL IMPAIRMENT PER MILLION, 2010 (THOUSANDS) 26FDA GUIDELINES FOR SELECTED PRODUCTS 27TABLE 6 FDA GUIDELINES FOR SELECTED PRODUCTS, 2001–2013 28REIMBURSEMENT SCENARIO 29CODING CHANGES FOR CARDIOLOGY 30Ablation Codes 30TABLE 7 ABLATION CODES 30TABLE 8 PHYSICIAN FEE SCHEDULE CODES 31Comparison of 2012 and 2013 Codes 32Case Study I 32TABLE 9 ATRIAL FIBRILLATION ABLATION, PULMONARY VEIN ISOLATION 32Case Study II 33TABLE 10 DIAGNOSTICS OF ELECTROPHYSIOLOGY STUDY 33MARKET DYNAMICS 34TECHNOLOGICAL DEVELOPMENTS 34HIGHER RISK OF CHRONIC ILLNESSES 34FIGURE 5 WORLD PROJECTED MORTALITY TRENDS DUE TO CARDIOVASCULARDISEASES, 2008, 2015, 2030 (%) 34FIGURE 6 U.S. CANCER DEMOGRAPHICS BY AGE AND GENDER, 2012 35ABLATION THERAPY REQUIRES LESS TIME 36LESS DAMAGE AND BLOOD LOSS 36RESTRAINTS FOR THE GLOBAL ABLATION DEVICES MARKET 37PRESSURE FROM REGULATORY AGENCIES 37INSURANCE SETTLEMENT ISSUES 37OPPORTUNITIES AND CHALLENGES FOR THE ABLATION DEVICES MARKET 38GROWING MARKETS IN EMERGING ECONOMIES 38NEED TO ENHANCE AWARENESS LEVELS 38
CHAPTER 4 ABLATION MARKET ANALYSIS BY TECHNOLOGIES 41 TABLE 11 GLOBAL MARKET FOR ABLATION DEVICES BY TECHNOLOGY, THROUGH2018 ($ MILLIONS) 41THERMAL TECHNOLOGY MARKET 41TABLE 12 GLOBAL MARKET FOR THERMAL ABLATION DEVICES BY TECHNOLOGY,THROUGH 2018 ($ MILLIONS) 42ELECTRICAL ABLATION THERAPY 42TABLE 13 GLOBAL MARKET FOR ELECTRICAL ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 42RADIATION TECHNOLOGY 43TABLE 14 GLOBAL MARKET FOR RADIATION ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 44Types of Radiation Ablation Techniques 45Intensity Modulated Radiation Therapy (IMRT) 45Image-Guided Radiation Therapy (IGRT) 45Helical Tomography 45Particle Therapy 46Stereotactic Radiotherapy 46Brachytherapy 46RADIO FREQUENCY (RFID) TECHNOLOGY 47TABLE 15 GLOBAL MARKET FOR RADIO FREQUENCY ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 47Uses of RFA 47The Key Applications of RFA 48Specific Application of RFID in Therapeutic Segments 48Treatment of Liver Cancer 48Treatment of Kidney Cancer 48Treatment of Lung Cancer 48Arrhythmias 49Arthritis Pain 49Treatment of Varicose Veins 49LIGHT 49TABLE 16 GLOBAL MARKET FOR LIGHT/LASER ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 50ULTRASOUND 51TABLE 17 GLOBAL MARKET FOR ULTRASOUND ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 51TABLE 18 HIFU STUDIES IN KIDNEY TISSUES IN SPECIFIED COUNTRIES 52HIFU in Prostate Cancer 52HIFU in Primary and Secondary Liver Cancers 53HIFU in Pancreatic Cancer 53HIFU in Bladder Cancer 53MICROWAVE 53TABLE 19 GLOBAL MARKET FOR MICROWAVE ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54HYDROTHERMAL 54TABLE 20 GLOBAL MARKET FOR HYDROTHERMAL ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54NONTHERMAL ABLATION TECHNOLOGY 55TABLE 21 GLOBAL MARKET FOR NONTHERMAL ABLATION TECHNOLOGY, THROUGH2018 ($ MILLIONS) 56CRYOABLATION 56TABLE 22 GLOBAL MARKET FOR CRYOABLATION TECHNOLOGY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 57HYDROMECHANICAL 57TABLE 23 GLOBAL MARKET FOR HYDROMECHANICAL TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 58
CHAPTER 5 ABLATION MARKET ANALYSIS BY PRODUCTS 60 ELECTRICAL 60TABLE 24 GLOBAL MARKET FOR ELECTRICAL ABLATOR BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS) 60ELECTRICAL ABLATORS 60TABLE 25 GLOBAL MARKET FOR ELECTRICAL ABLATOR REVENUE BY PRODUCT,THROUGH 2018 ($ MILLIONS) 61Argon Plasma/Beam Coagulator 61Irreversible Electroporation 61ELECTRONIC BRACHYTHERAPY 62RADIATION 62TABLE 26 GLOBAL MARKET FOR RADIATION PRODUCTS BY REVENUE, THROUGH2018 ($ MILLIONS) 62BRACHYTHERAPY 62TABLE 27 GLOBAL MARKET FOR BRACHYTHERAPY ABLATOR BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 63High-Dose-Rate (HDR) Brachytherapy 63TABLE 28 GLOBAL MARKET FOR HIGH-DOSE-RATE BRACHYTHERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 63Pulsed-Dose-Rate Brachytherapy 64TABLE 29 GLOBAL MARKET FOR PULSE-DOSE-RATE BRACHYTHERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 64Permanent Seed Brachytherapy or Low-Dose-Rate (LDR)Brachytherapy 64TABLE 30 GLOBAL MARKET FOR PERMANENT SEED BRACHYTHERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 65STEREOTACTIC RADIOSURGERY AND STEREOTACTIC RADIOTHERAPY 65TABLE 31 GLOBAL MARKET FOR STEREOTACTIC RADIOSURGERY (SRS) ANDSTEREOTACTIC RADIOTHERAPY (SRT) MARKET REVENUE BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS)66IMAGE-GUIDED RADIATION THERAPY (IGRT) 66TABLE 32 GLOBAL MARKET FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67INTENSITY-MODULATED RADIATION THERAPY (IMRT) 67TABLE 33 GLOBAL MARKET FOR INTENSITY-MODULATED RADIATION THERAPY(IMRT) BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67STEREOTACTIC BODY RADIATION THERAPY (SBRT) 68TABLE 34 GLOBAL MARKET FOR STEREOTACTIC BODY RADIATION THERAPY (SBRT)BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 68PROTON BEAM THERAPY 68TABLE 35 GLOBAL MARKET FOR PROTON BEAM THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 69RADIO FREQUENCY 69TABLE 36 GLOBAL MARKET FOR RADIO FREQUENCY ABLATOR MARKET BYPRODUCT, THROUGH 2018 ($ MILLIONS) 69TEMPERATURE-CONTROLLED RADIO FREQUENCY ABLATION DEVICES 70TABLE 37 GLOBAL MARKET FOR TEMPERATURE-CONTROLLED RADIO FREQUENCYABLATION DEVICES BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 70FLUID-COOLED RF ABLATION 70TABLE 38 GLOBAL MARKET FOR FLUID COOLED RF ABLATION DEVICES BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71THE ROBOTIC CATHETER MANIPULATION SYSTEM 71TABLE 39 GLOBAL MARKET FOR CATHETER MANIPULATION SYSTEM DEVICES BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71LIGHT/LASER 72TABLE 40 GLOBAL MARKET FOR LIGHT/LASER BY PRODUCT, THROUGH 2018 ($MILLIONS) 72COLD LASER 72TABLE 41 GLOBAL MARKET FOR COLD LASER DEVICES BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS) 73EXCIMER LASER 73TABLE 42 GLOBAL MARKET FOR EXCIMER LASER DEVICES BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 73ULTRASOUND 74TABLE 43 GLOBAL MARKET FOR ULTRASOUND ABLATION PRODUCTS, THROUGH2018 ($ MILLIONS) 74HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 74TABLE 44 GLOBAL MARKET FOR HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 75MAGNETIC RESONANCE-GUIDED ULTRASOUND (MRGUS) 75TABLE 45 GLOBAL MARKET FOR MAGNETIC RESONANCE–GUIDED ULTRASOUND(MRGUS) ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76ULTRASONIC SURGICAL SYSTEMS 76TABLE 46 GLOBAL MARKET FOR ULTRASONIC SURGICAL SYSTEMS BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY 77TABLE 47 GLOBAL MARKET FOR EXTRACORPOREAL SHOCKWAVE LITHOTRIPSYPRODUCT BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 77MICROWAVE ABLATION 77TABLE 48 GLOBAL MARKET FOR MICROWAVE ABLATION PRODUCT BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 78HYDROTHERMAL ABLATION/ ENDOMETRIAL HYDROTHERMAL BALLOONABLATION DEVICES 78TABLE 49 GLOBAL MARKET FOR HYDROTHERMAL ABLATION PRODUCT BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 79CRYOABLATION 79TABLE 50 GLOBAL MARKET FOR CRYOABLATION PRODUCTS BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 80TISSUE CONTACT PROBE 80TISSUE SPRAY PROBE 80EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 81ADVANCEMENT IN ROBOTIC ABLATION TECHNIQUE 81VARIOUS PROCEDURES THAT ARE ROBOTIC IN NATURE 82STEERABLE CATHETERS 82HEARTLANDER 82ROBOTIC RADIOTHERAPY 82ROBOTIC ABLATION FOR ARRHYTHMIA 82LEADING ROBOTIC SYSTEMS USED IN CATHETER ABLATION 83Niobe (Stereotaxis) 83Sensei (Hansen Medical) 83Amigo (Catheter Robotics) 83Artis Zeego (Siemens) 83TABLE 51 GLOBAL MARKET FOR ROBOTIC ABLATION BY PRODUCT, THROUGH 2018($ MILLIONS) 83
CHAPTER 6 ABLATION MARKET ANALYSIS BY PROCEDURES 86 TABLE 52 GLOBAL ABLATION MARKET BY PROCEDURE, THROUGH 2018 ($MILLIONS) 86AESTHETICS-SKIN REJUVENATION AND TIGHTENING 86TABLE 53 GLOBAL MARKET FOR AESTHETICS-SKIN REJUVENATION ANDTIGHTENING BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 87LASER SKIN REJUVENATION 87ILLUSTRATION: VICTORIAN COSMETIC INSTITUTE'S CASE STUDIES 87RADIO FREQUENCY (RF) FOR FACIAL SKIN REJUVENATION 88AESTHETICS-BODY SCULPTING, FAT REDUCTION AND REDUCTION IN THEAPPEARANCE OF CELLULITE 89TABLE 54 GLOBAL MARKET FOR AESTHETICS-BODY SCULPTING, FAT REDUCTIONAND REDUCTION IN THE APPEARANCE OF CELLULITE ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)89HIFU FOR FAT REDUCTION 89ILLUSTRATION: ELSEVIER HEALTH JOURNAL 90VACUUM MASSAGE FOR CELLULITE REDUCTION 90BENIGN PROSTATIC HYPERPLASIA ABLATION 91TABLE 55 GLOBAL MARKET FOR BENIGN PROSTATIC HYPERPLASIA ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 91GREENLIGHT LASER PROCEDURE FOR BENIGN PROSTATE HYPERPLASIA 91ILLUSTRATION: EUROPEAN UROLOGY CENTER 91THERMOTHERAPY FOR BENIGN PROSTATE HYPERPLASIA 92TRANSURETHRAL NEEDLE ABLATION 92TABLE 56 GLOBAL MARKET FOR TRANSURETHRAL NEEDLE ABLATION PROCEDUREBY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 93ILLUSTRATION: DIVISION OF UROLOGY, JOHANNESBURG HOSPITAL, SOUTHAFRICA 93LASER- AND OTHER ENERGY-BASED THERAPIES/HOLMIUM LASERABLATION/ENUCLEATION OF THE PROSTATE 94HOLMIUM LASER ENUCLEATION OF PROSTATE CANCER HLEOP 94TABLE 57 GLOBAL MARKET FOR LASER- AND OTHER ENERGY-BASED ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 94ILLUSTRATION 94ABLATION FOR ATRIAL FIBRILLATION 95TABLE 58 GLOBAL MARKET FOR ATRIAL FIBRILLATION ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 95PAROXYSMAL ATRIAL FIBRILLATION 96PERSISTENT ATRIAL FIBRILLATION 96CANCER/TUMOR ABLATION 96TABLE 59 GLOBAL MARKET FOR CANCER ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 97MENORRHAGIA/ENDOMETRIAL ABLATION 97TABLE 60 GLOBAL MARKET FOR MENORRHAGIA/ENDOMETRIAL ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 98HEATED BALLOON PROCEDURE 98SPINAL DECOMPRESSION AND DENERVATION 99TABLE 61 GLOBAL MARKET FOR SPINAL DECOMPRESSION AND DENERVATIONABLATION PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 99DIAGNOSTIC MEDIAL BRANCH BLOCK (MBB) 99RADIO FREQUENCY ABLATION (RFA) FOR BACK PAIN 100STRESS URINARY INCONTINENCE 100TABLE 62 GLOBAL MARKET FOR STRESS URINARY INCONTINENCE ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 101TRANSURETHRAL RADIO FREQUENCY COLLAGEN DENATURATION 101VARICOSE VEIN ABLATION 101TABLE 63 GLOBAL MARKET FOR VARICOSE VEIN ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 102RADIO FREQUENCY ABLATION (RFA) FOR VARICOSE VEINS 102UTERINE FIBROIDS 103TABLE 64 GLOBAL MARKET FOR UTERINE FIBROIDS ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 103HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) FOR UTERINE FIBROIDS 103OTHER PROCEDURES 104ELASA EYE SURGERY 104
CHAPTER 7 ABLATION MARKET ANALYSIS BY THERAPEUTICS 106 TABLE 65 GLOBAL MARKET FOR ABLATION THERAPEUTICS, THROUGH 2018 ($MILLIONS) 106CANCER/ONCOLOGY 106TABLE 66 GLOBAL MARKET FOR CANCER ABLATION THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 107CARDIOVASCULAR 107TABLE 67 GLOBAL MARKET FOR CARDIOVASCULAR ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 108OPHTHALMOLOGY 109TABLE 68 GLOBAL MARKET FOR OPHTHALMOLOGY ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 109COSMETOLOGY 110GYNECOLOGY 111TABLE 69 GLOBAL MARKET FOR GYNECOLOGY ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 112UROLOGY 112TABLE 70 GLOBAL MARKET FOR UROLOGY ABLATION THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 113CRYOABLATION FOR PROSTATE CANCER 113ORTHOPEDICS 114TABLE 71 GLOBAL MARKET FOR ORTHOPEDICS THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 114RADIO FREQUENCY ABLATION (RFA) FOR ORTHOPEDIC TREATMENT 114PAIN MANAGEMENT 115CRYOABLATION IN PAIN MANAGEMENT 115OTHERS 116TABLE 72 GLOBAL MARKET FOR OTHER THERAPY BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS) 116COBLATION FOR TONSILLITIS 116PORT-WINE STAINS 117ABLATION OF PORT-WINE STAINS 117
CHAPTER 8 COMPETITIVE LANDSCAPE 119 FIGURE 7 KEY COMPETITIVE STRATEGIES*, 2010-2013 (%) 119PRODUCT LAUNCH 120FIGURE 8 PRODUCT LAUNCH BY COMPANY*, 2010–2013 (%) 121TABLE 73 LIST OF KEY PRODUCT LAUNCHES ANNOUNCED, 2010-2013 122MERGERS AND ACQUISITIONS STRATEGY 124FIGURE 9 MERGERS AND ACQUISITIONS BY COMPANIES*, 2010-2013 (%) 124TABLE 74 MERGERS AND ACQUISITIONS STRATEGIES BY COMPANIES, 2010-2013 126PARTNERSHIP AND COLLABORATION STRATEGY 127FIGURE 10 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES*,2010-2013 127TABLE 75 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES,2010-2012 129APPROVALS AND OTHER STRATEGIES 130FIGURE 11 APPROVALS AND OTHER STRATEGIES BY COMPANIES*, 2010-2013 (%) 131TABLE 76 LIST OF APPROVALS AND OTHER STRATEGIES ANNOUNCED, 2010–2013 132
CHAPTER 9 GEOGRAPHICAL ANALYSIS 136 NORTH AMERICA 136TABLE 77 ABLATION MARKET ESTIMATION FOR NORTH AMERICA, THROUGH 2018($ MILLIONS) 136EUROPE 137TABLE 78 ABLATION MARKET ESTIMATION FOR EUROPE, THROUGH 2018 ($MILLIONS) 137ASIA PACIFIC 138TABLE 79 ABLATION MARKET ESTIMATION FOR ASIA PACIFIC, THROUGH 2018 ($MILLIONS) 138REST OF WORLD (ROW) 139TABLE 80 ABLATION MARKET ESTIMATION FOR ROW, THROUGH 2018 ($ MILLIONS) 140
CHAPTER 10 PATENT ANALYSIS 142 FIGURE 12 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE AND JAPAN,2008-2013 (%) 142THE U.S. PATENT ANALYSIS BY APPLICATION 142FIGURE 13 U.S. PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 143U.S. PATENT ANALYSIS BY MARKET PARTICIPANTS 144FIGURE 14 U.S. PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 144EUROPE PATENT ANALYSIS BY TECHNOLOGY 145FIGURE 15 EUROPE PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 145EUROPE PATENT ANALYSIS BY MARKET PARTICIPANTS 146FIGURE 16 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 146JAPAN PATENT ANALYSIS BY TECHNOLOGY 147FIGURE 17 JAPAN PATENT ANALYSIS BY TECHNOLOGY, 2008–2013 (%) 147JAPAN PATENT ANALYSIS BY MARKET PARTICIPANTS 148FIGURE 18 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 148
CHAPTER 11 COMPANY PROFILES 150 ACCURAY INC 150ACCURAY PRODUCT PORTFOLIO 150TABLE 81 ACCURAY RECENT DEVELOPMENTS, 2010-2012 151TABLE 82 ACCURAY FINANCIALS, 2010-2012 151ALCON LABORATORIES INC. 151ABLATION PRODUCT PORTFOLIO 152TABLE 83 ALCON RECENT DEVELOPMENT, 2012 152TABLE 84 ALCON FINANCIALS, 2010–2012 152ANGIODYNAMICS INC. 153ABLATION PRODUCT PORTFOLIO 153TABLE 85 ANGIODYNAMICS RECENT DEVELOPMENTS, 2010-2012 154TABLE 86 ANGIODYNAMICS FINANCIALS, 2010-2012 154ARTHROCARE CORPORATION 155ABLATION PRODUCT PORTFOLIO 155TABLE 87 ARTHROCARE RECENT DEVELOPMENTS, 2010 156TABLE 88 ARTHROCARE CORPORATION FINANCIALS, 2010-2012 156ATRICURE INC. 156ABLATION PRODUCT PORTFOLIO 157TABLE 89 ATRICURE RECENT DEVELOPMENTS, 2010-2011 157TABLE 90 ATRICURE FINANCIALS, 2010-2012 158BIOSENSE WEBSTER 158ABLATION PRODUCT PORTFOLIO 158TABLE 91 BIOSENSE WEBSTER RECENT DEVELOPMENTS, 2010-2012 159TABLE 92 BIOSENSE WEBSTER FINANCIALS, 2010-2012 159BOSTON SCIENTIFIC CORPORATION 160ABLATION PRODUCT PORTFOLIO 160TABLE 93 BOSTON SCIENTIFIC CORPORATION RECENT DEVELOPMENTS, 2010-2012 161TABLE 94 BOSTON SCIENTIFIC CORPORATION FINANCIALS, 2010-2012 161BSD MEDICAL CORPORATION 161ABLATION PRODUCT PORTFOLIO 162TABLE 95 BSD MEDICALS RECENT DEVELOPMENTS, 2010-2012 162TABLE 96 BSD MEDICALS FINANCIALS, 2010-2012 163C.R. BARD INC. 163ABLATION PRODUCT PORTFOLIO 163TABLE 97 C.R. BARD RECENT DEVELOPMENTS, 2011-2012 164TABLE 98 C.R. BARD FINANCIALS, 2010-2012 164CONMED CORPORATION 164ABLATION PRODUCT PORTFOLIO 165TABLE 99 CONMED RECENT DEVELOPMENTS, 2010 165TABLE 100 CONMED FINANCIALS, 2010-2012 166COVIDIEN 166ABLATION PRODUCT PORTFOLIO 166TABLE 101 COVIDIEN RECENT DEVELOPMENTS, 2011-2013 167TABLE 102 COVIDIEN FINANCIALS, 2010-2012 168ELEKTA AB 168ABLATION PRODUCT PORTFOLIO 168TABLE 103 ELEKTA AB RECENT DEVELOPMENTS, 2010–2013 169TABLE 104 ELEKTA AB FINANCIALS, 2010-2012 170ENDOSENSE SA 170ABLATION PRODUCT PORTFOLIO 170TABLE 105 ENDOSENSE RECENT DEVELOPMENTS (BEFORE ACQUISITION),2010-2011 171GALIL MEDICAL LTD. 171ABLATION PRODUCT PORTFOLIO 171TABLE 106 GALIL MEDICAL LTD RECENT DEVELOPMENTS, 2011-2012 172MEDTRONIC INC 172ABLATION PRODUCT PORTFOLIO 172TABLE 107 MEDTRONIC RECENT DEVELOPMENTS, 2010-2013 173TABLE 108 MEDTRONIC FINANCIALS, 2010-2012 174MISONIX INC. 174ABLATION PRODUCT PORTFOLIO 174TABLE 109 MISONIX INC RECENT DEVELOPMENTS, 2010-2012 175TABLE 110 MISONIX FINANCIALS, 2010-2012 176OLYMPUS CORPORATION 176ABLATION PRODUCT PORTFOLIO 176TABLE 111 OLYMPUS RECENT DEVELOPMENTS, 2010-2012 177TABLE 112 OLYMPUS FINANCIALS, 2010-2012 177ST. JUDE MEDICAL INC. 177ABLATION PRODUCT PORTFOLIO 178TABLE 113 ST. JUDE MEDICAL RECENT DEVELOPMENTS, 2010–2013 178TABLE 114 ST. JUDE MEDICAL FINANCIALS, 2010-2012 179UROLOGIX INC. 179ABLATION PRODUCT PORTFOLIO 179TABLE 115 UROLOGIX RECENT DEVELOPMENTS, 2011-2012 180TABLE 116 UROLOGIX FINANCIALS, 2010-2012 180VARIAN MEDICAL SYSTEMS INC. 180ABLATION PRODUCT PORTFOLIO 181TABLE 117 VARIAN MEDICAL SYSTEMS RECENT DEVELOPMENTS, 2010-2012 181TABLE 118 VARIAN MEDICAL SYSTEMS INC, 2010-2012 182
CHAPTER 12 APPENDIX 184 LIST OF U.S. PATENTS 184TABLE 119 LIST OF PATENTS: UNITED STATES, 2008-2013 184LIST OF PATENTS: EUROPE 188TABLE 120 LIST OF PATENTS: EUROPE, 2008-2013 188LIST OF PATENTS: JAPAN 194TABLE 121 LIST OF PATENTS: JAPAN, 2008-2013 194
LIST OF TABLES: SUMMARY TABLE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 8TABLE 1 DEVICES THAT ARE NOT YET APPROVED FOR THE TREATMENT OF ATRIALFIBRILLATION 17TABLE 2 CANCER DEMOGRAPHICS IN THE U.S., 2013 (ESTIMATED) 21TABLE 3 CARDIOVASCULAR DEMOGRAPHICS IN THE U.S. BY AGE, 2010 (%) 23TABLE 4 EUROPEAN UNION STATISTICS OF CARDIOVASCULAR DISEASES ANDCIRCULATORY DISEASES, 2010 24TABLE 5 VISUAL IMPAIRMENT STATISTICS U.S., 2000 AND 2010 25TABLE 6 FDA GUIDELINES FOR SELECTED PRODUCTS, 2001–2013 28TABLE 7 ABLATION CODES 30TABLE 8 PHYSICIAN FEE SCHEDULE CODES 31TABLE 9 ATRIAL FIBRILLATION ABLATION, PULMONARY VEIN ISOLATION 32TABLE 10 DIAGNOSTICS OF ELECTROPHYSIOLOGY STUDY 33TABLE 11 GLOBAL MARKET FOR ABLATION DEVICES BY TECHNOLOGY, THROUGH2018 ($ MILLIONS) 41TABLE 12 GLOBAL MARKET FOR THERMAL ABLATION DEVICES BY TECHNOLOGY,THROUGH 2018 ($ MILLIONS) 42TABLE 13 GLOBAL MARKET FOR ELECTRICAL ABLATION THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 42TABLE 14 GLOBAL MARKET FOR RADIATION ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 44TABLE 15 GLOBAL MARKET FOR RADIO FREQUENCY ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 47TABLE 16 GLOBAL MARKET FOR LIGHT/LASER ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 50TABLE 17 GLOBAL MARKET FOR ULTRASOUND ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 51TABLE 18 HIFU STUDIES IN KIDNEY TISSUES IN SPECIFIED COUNTRIES 52TABLE 19 GLOBAL MARKET FOR MICROWAVE ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54TABLE 20 GLOBAL MARKET FOR HYDROTHERMAL ABLATION TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 54TABLE 21 GLOBAL MARKET FOR NONTHERMAL ABLATION TECHNOLOGY, THROUGH2018 ($ MILLIONS) 56TABLE 22 GLOBAL MARKET FOR CRYOABLATION TECHNOLOGY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 57TABLE 23 GLOBAL MARKET FOR HYDROMECHANICAL TECHNOLOGY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 58TABLE 24 GLOBAL MARKET FOR ELECTRICAL ABLATOR BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS) 60TABLE 25 GLOBAL MARKET FOR ELECTRICAL ABLATOR REVENUE BY PRODUCT,THROUGH 2018 ($ MILLIONS) 61TABLE 26 GLOBAL MARKET FOR RADIATION PRODUCTS BY REVENUE, THROUGH2018 ($ MILLIONS) 62TABLE 27 GLOBAL MARKET FOR BRACHYTHERAPY ABLATOR BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 63TABLE 28 GLOBAL MARKET FOR HIGH-DOSE-RATE BRACHYTHERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 63TABLE 29 GLOBAL MARKET FOR PULSE-DOSE-RATE BRACHYTHERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 64TABLE 30 GLOBAL MARKET FOR PERMANENT SEED BRACHYTHERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 65TABLE 31 GLOBAL MARKET FOR STEREOTACTIC RADIOSURGERY (SRS) ANDSTEREOTACTIC RADIOTHERAPY (SRT) MARKET REVENUE BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS)66TABLE 32 GLOBAL MARKET FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67TABLE 33 GLOBAL MARKET FOR INTENSITY-MODULATED RADIATION THERAPY (IMRT)BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 67TABLE 34 GLOBAL MARKET FOR STEREOTACTIC BODY RADIATION THERAPY (SBRT)BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 68TABLE 35 GLOBAL MARKET FOR PROTON BEAM THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 69TABLE 36 GLOBAL MARKET FOR RADIO FREQUENCY ABLATOR MARKET BY PRODUCT,THROUGH 2018 ($ MILLIONS) 69TABLE 37 GLOBAL MARKET FOR TEMPERATURE-CONTROLLED RADIO FREQUENCYABLATION DEVICES BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 70TABLE 38 GLOBAL MARKET FOR FLUID COOLED RF ABLATION DEVICES BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71TABLE 39 GLOBAL MARKET FOR CATHETER MANIPULATION SYSTEM DEVICES BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 71TABLE 40 GLOBAL MARKET FOR LIGHT/LASER BY PRODUCT, THROUGH 2018 ($MILLIONS) 72TABLE 41 GLOBAL MARKET FOR COLD LASER DEVICES BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS) 73TABLE 42 GLOBAL MARKET FOR EXCIMER LASER DEVICES BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 73TABLE 43 GLOBAL MARKET FOR ULTRASOUND ABLATION PRODUCTS, THROUGH2018 ($ MILLIONS) 74TABLE 44 GLOBAL MARKET FOR HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 75TABLE 45 GLOBAL MARKET FOR MAGNETIC RESONANCE–GUIDED ULTRASOUND(MRGUS) ABLATORS BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76TABLE 46 GLOBAL MARKET FOR ULTRASONIC SURGICAL SYSTEMS BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 76TABLE 47 GLOBAL MARKET FOR EXTRACORPOREAL SHOCKWAVE LITHOTRIPSYPRODUCT BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 77TABLE 48 GLOBAL MARKET FOR MICROWAVE ABLATION PRODUCT BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 78TABLE 49 GLOBAL MARKET FOR HYDROTHERMAL ABLATION PRODUCT BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 79TABLE 50 GLOBAL MARKET FOR CRYOABLATION PRODUCTS BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 80TABLE 51 GLOBAL MARKET FOR ROBOTIC ABLATION BY PRODUCT, THROUGH 2018($ MILLIONS) 83TABLE 52 GLOBAL ABLATION MARKET BY PROCEDURE, THROUGH 2018 ($ MILLIONS) 86TABLE 53 GLOBAL MARKET FOR AESTHETICS-SKIN REJUVENATION AND TIGHTENINGBY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 87TABLE 54 GLOBAL MARKET FOR AESTHETICS-BODY SCULPTING, FAT REDUCTIONAND REDUCTION IN THE APPEARANCE OF CELLULITE ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)89TABLE 55 GLOBAL MARKET FOR BENIGN PROSTATIC HYPERPLASIA ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 91TABLE 56 GLOBAL MARKET FOR TRANSURETHRAL NEEDLE ABLATION PROCEDUREBY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 93TABLE 57 GLOBAL MARKET FOR LASER- AND OTHER ENERGY-BASED ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 94TABLE 58 GLOBAL MARKET FOR ATRIAL FIBRILLATION ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 95TABLE 59 GLOBAL MARKET FOR CANCER ABLATION PROCEDURE BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 97TABLE 60 GLOBAL MARKET FOR MENORRHAGIA/ENDOMETRIAL ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 98TABLE 61 GLOBAL MARKET FOR SPINAL DECOMPRESSION AND DENERVATIONABLATION PROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 99TABLE 62 GLOBAL MARKET FOR STRESS URINARY INCONTINENCE ABLATIONPROCEDURE BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 101TABLE 63 GLOBAL MARKET FOR VARICOSE VEIN ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 102TABLE 64 GLOBAL MARKET FOR UTERINE FIBROIDS ABLATION PROCEDURE BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 103TABLE 65 GLOBAL MARKET FOR ABLATION THERAPEUTICS, THROUGH 2018 ($MILLIONS) 106TABLE 66 GLOBAL MARKET FOR CANCER ABLATION THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 107TABLE 67 GLOBAL MARKET FOR CARDIOVASCULAR ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 108TABLE 68 GLOBAL MARKET FOR OPHTHALMOLOGY ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 109TABLE 69 GLOBAL MARKET FOR GYNECOLOGY ABLATION THERAPY BYGEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS) 112TABLE 70 GLOBAL MARKET FOR UROLOGY ABLATION THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 113TABLE 71 GLOBAL MARKET FOR ORTHOPEDICS THERAPY BY GEOGRAPHICALREGION, THROUGH 2018 ($ MILLIONS) 114TABLE 72 GLOBAL MARKET FOR OTHER THERAPY BY GEOGRAPHICAL REGION,THROUGH 2018 ($ MILLIONS) 116TABLE 73 LIST OF KEY PRODUCT LAUNCHES ANNOUNCED, 2010-2013 122TABLE 74 MERGERS AND ACQUISITIONS STRATEGIES BY COMPANIES, 2010-2013 126TABLE 75 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES,2010-2012 129TABLE 76 LIST OF APPROVALS AND OTHER STRATEGIES ANNOUNCED, 2010–2013 132TABLE 77 ABLATION MARKET ESTIMATION FOR NORTH AMERICA, THROUGH 2018 ($MILLIONS) 136TABLE 78 ABLATION MARKET ESTIMATION FOR EUROPE, THROUGH 2018 ($MILLIONS) 137TABLE 79 ABLATION MARKET ESTIMATION FOR ASIA PACIFIC, THROUGH 2018 ($MILLIONS) 138TABLE 80 ABLATION MARKET ESTIMATION FOR ROW, THROUGH 2018 ($ MILLIONS) 140TABLE 81 ACCURAY RECENT DEVELOPMENTS, 2010-2012 151TABLE 82 ACCURAY FINANCIALS, 2010-2012 151TABLE 83 ALCON RECENT DEVELOPMENT, 2012 152TABLE 84 ALCON FINANCIALS, 2010–2012 152TABLE 85 ANGIODYNAMICS RECENT DEVELOPMENTS, 2010-2012 154TABLE 86 ANGIODYNAMICS FINANCIALS, 2010-2012 154TABLE 87 ARTHROCARE RECENT DEVELOPMENTS, 2010 156TABLE 88 ARTHROCARE CORPORATION FINANCIALS, 2010-2012 156TABLE 89 ATRICURE RECENT DEVELOPMENTS, 2010-2011 157TABLE 90 ATRICURE FINANCIALS, 2010-2012 158TABLE 91 BIOSENSE WEBSTER RECENT DEVELOPMENTS, 2010-2012 159TABLE 92 BIOSENSE WEBSTER FINANCIALS, 2010-2012 159TABLE 93 BOSTON SCIENTIFIC CORPORATION RECENT DEVELOPMENTS, 2010-2012 161TABLE 94 BOSTON SCIENTIFIC CORPORATION FINANCIALS, 2010-2012 161TABLE 95 BSD MEDICALS RECENT DEVELOPMENTS, 2010-2012 162TABLE 96 BSD MEDICALS FINANCIALS, 2010-2012 163TABLE 97 C.R. BARD RECENT DEVELOPMENTS, 2011-2012 164TABLE 98 C.R. BARD FINANCIALS, 2010-2012 164TABLE 99 CONMED RECENT DEVELOPMENTS, 2010 165TABLE 100 CONMED FINANCIALS, 2010-2012 166TABLE 101 COVIDIEN RECENT DEVELOPMENTS, 2011-2013 167TABLE 102 COVIDIEN FINANCIALS, 2010-2012 168TABLE 103 ELEKTA AB RECENT DEVELOPMENTS, 2010–2013 169TABLE 104 ELEKTA AB FINANCIALS, 2010-2012 170TABLE 105 ENDOSENSE RECENT DEVELOPMENTS (BEFORE ACQUISITION),2010-2011 171TABLE 106 GALIL MEDICAL LTD RECENT DEVELOPMENTS, 2011-2012 172TABLE 107 MEDTRONIC RECENT DEVELOPMENTS, 2010-2013 173TABLE 108 MEDTRONIC FINANCIALS, 2010-2012 174TABLE 109 MISONIX INC RECENT DEVELOPMENTS, 2010-2012 175TABLE 110 MISONIX FINANCIALS, 2010-2012 176TABLE 111 OLYMPUS RECENT DEVELOPMENTS, 2010-2012 177TABLE 112 OLYMPUS FINANCIALS, 2010-2012 177TABLE 113 ST. JUDE MEDICAL RECENT DEVELOPMENTS, 2010–2013 178TABLE 114 ST. JUDE MEDICAL FINANCIALS, 2010-2012 179TABLE 115 UROLOGIX RECENT DEVELOPMENTS, 2011-2012 180TABLE 116 UROLOGIX FINANCIALS, 2010-2012 180TABLE 117 VARIAN MEDICAL SYSTEMS RECENT DEVELOPMENTS, 2010-2012 181TABLE 118 VARIAN MEDICAL SYSTEMS INC, 2010-2012 182TABLE 119 LIST OF PATENTS: UNITED STATES, 2008-2013 184TABLE 120 LIST OF PATENTS: EUROPE, 2008-2013 188TABLE 121 LIST OF PATENTS: JAPAN, 2008-2013 194
LIST OF FIGURES: SUMMARY FIGURE GLOBAL MARKET FOR ABLATION DEVICES BY GEOGRAPHICALREGION, 2012-2018 ($ MILLIONS) 8FIGURE 1 DEATHS DUE TO PROSTATE CANCER IN THE U.K., 2011 (%) 22FIGURE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN ADULTS IN THE U.S. AGEGROUP 45-64 YEARS, 2000 AND 2010 (%) 24FIGURE 3 CAUSES OF VISUAL IMPAIRMENT, 2010 (%) 25FIGURE 4 VISUAL IMPAIRMENT PER MILLION, 2010 (THOUSANDS) 26FIGURE 5 WORLD PROJECTED MORTALITY TRENDS DUE TO CARDIOVASCULARDISEASES, 2008, 2015, 2030 (%) 34FIGURE 6 U.S. CANCER DEMOGRAPHICS BY AGE AND GENDER, 2012 35FIGURE 7 KEY COMPETITIVE STRATEGIES*, 2010-2013 (%) 119FIGURE 8 PRODUCT LAUNCH BY COMPANY*, 2010–2013 (%) 121FIGURE 9 MERGERS AND ACQUISITIONS BY COMPANIES*, 2010-2013 (%) 124FIGURE 10 PARTNERSHIP AND COLLABORATION STRATEGIES BY COMPANIES*,2010-2013 127FIGURE 11 APPROVALS AND OTHER STRATEGIES BY COMPANIES*, 2010-2013 (%) 131FIGURE 12 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE AND JAPAN,2008-2013 (%) 142FIGURE 13 U.S. PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 143FIGURE 14 U.S. PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 144FIGURE 15 EUROPE PATENT ANALYSIS BY TECHNOLOGY, 2008-2013 (%) 145FIGURE 16 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 146FIGURE 17 JAPAN PATENT ANALYSIS BY TECHNOLOGY, 2008–2013 (%) 147FIGURE 18 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANTS, 2008-2013 (%) 148
Read the full report:Ablation Devices: Technologies and Global Markets https://www.reportbuyer.com/product/2009158/Ablation-Devices-Technologies-and-Global-Markets.html
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
SOURCE ReportBuyer
